Olumiant and Xeljanz XR Will Be the Latest Rheumatoid Arthritis Meds

December 2018

Olumiant (baricitinib) and Xeljanz XR (tofacitinib) will be new once-daily oral meds for rheumatoid arthritis (RA).

Olumiant (oh-LOO-mee-ant) is the second "Janus kinase (JAK) inhibitor" for RA on the market after Xeljanz.

And once-daily Xeljanz XR may simplify dosing over twice-daily Xeljanz.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Operations & Management Streamline Processes to Return Expired or Unusable Meds
Med Safety Extinguish Issues With Meds That Can Catch Fire
Compounding Help Your Pharmacy Meet the New Non-Sterile Compounding Requirements
Women's Health Watch for Orilissa, a New Med for Endometriosis
Antithrombotics Avoid Errors With the New Strength of Xarelto
Biosimilars Clear Up Confusion About Biosimilars
Supplements Steer Patients Asking About Activated Charcoal to the Pharmacist
Rheumatoid Arthritis Olumiant and Xeljanz XR Will Be the Latest Rheumatoid Arthritis Meds
Raynaud's Know How Treatments for Raynaud's Phenomenon Stack Up
Pediatrics Ensure Kids Get the Right Med for Croup
Hyponatremia Look Out for Meds That May Lead to Low Sodium Levels